The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2022 | Factors predicting outcomes in patients with AL amyloidosis treated with daratumumab
Camille Vanessa Edwards, MD, Boston University School of Medicine, Boston, MA, comments on the results of a study investigating factors that can predict the outcomes of patients with AL amyloidosis treated with daratumumab. The study found that an NT-proBNP greater than 8500, gain of chromosome 1q, and a treatment period of less than 12 months were all associated with poorer outcomes in this patient population. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
